List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/109424/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	COVIDâ€19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. British Journal of Haematology, 2022, 196, 559-565.	2.5	20
2	Obituary of Prof. Michele Baccarani. Mediterranean Journal of Hematology and Infectious Diseases, 2022, 14, e2022015.	1.3	0
3	Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). Frontiers in Oncology, 2022, 12, 835563.	2.8	6
4	Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUXâ€ЮL study. British Journal of Haematology, 2022, 197, 190-200.	2.5	7
5	Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual diseaseâ€positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial. American Journal of Hematology, 2022, 97, .	4.1	1
6	Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study. Frontiers in Oncology, 2022, 12, 839915.	2.8	10
7	Chronic Myeloid Leukemia and Pregnancy: When Dreams Meet Reality. State of the Art, Management and Outcome of 41 Cases, Nilotinib Placental Transfer. Journal of Clinical Medicine, 2022, 11, 1801.	2.4	10
8	Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronicâ€phase myelofibrosis. Cancer, 2022, 128, 2449-2454.	4.1	7
9	Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 669-678.	1.3	10
10	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. British Journal of Haematology, 2021, 193, 356-368.	2.5	19
11	Rearrangements of ATP5Lâ€KMT2A in acute lymphoblastic leukaemia. British Journal of Haematology, 2021, 192, e139-e144.	2.5	3
12	Nextâ€generation sequencing improves BCRâ€ABL1 mutation detection in Philadelphia chromosomeâ€positive acute lymphoblastic leukaemia. British Journal of Haematology, 2021, 193, 271-279.	2.5	4
13	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer Journal, 2021, 11, 4.	6.2	41
14	Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study. Cancer Medicine, 2021, 10, 1726-1737.	2.8	9
15	Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia. Frontiers in Oncology, 2021, 11, 631570.	2.8	5
16	Bosutinib in the realâ€life treatment of chronic myeloid leukemia patients aged >65Âyears resistant/intolerant to previous tyrosineâ€kinase inhibitors. Hematological Oncology, 2021, 39, 401-408.	1.7	8
17	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. Cancer, 2021, 127, 2657-2665.	4.1	14
18	Case Report: Very Late, Atypical Extra-Medullary Relapse in a Patient With Acute Promyelocytic Leukemia (APL) Rescued With a Transplant-Free Approach. Frontiers in Oncology, 2021, 11, 699886.	2.8	0

#	Article	IF	CITATIONS
19	CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin. Cancers, 2021, 13, 3214.	3.7	20
20	The serological prevalence of SARSâ€CoVâ€2 infection in patients with chronic myeloid leukemia is similar to that in the general population. Cancer Medicine, 2021, 10, 6310-6316.	2.8	13
21	Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. Frontiers in Oncology, 2021, 11, 739171.	2.8	6
22	CML-182: SETD2 Loss of Function Induces Genomic Instability in CML and May Contribute to Disease Progression to Blast Crisis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S329-S330.	0.4	0
23	Chronic Myeloid Leukemia and Pregnancy: "Per Aspera Ad Astra― Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S153-S155.	0.4	1
24	Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. Acta Oncológica, 2021, 60, 1527-1533.	1.8	2
25	Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. Blood Advances, 2021, 5, 4504-4514.	5.2	14
26	Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. Annals of Hematology, 2021, 100, 2005-2014.	1.8	14
27	Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial. Blood, 2021, 138, 3603-3603.	1.4	6
28	Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial. Blood, 2021, 138, 1475-1475.	1.4	5
29	Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials. Blood, 2021, 138, 2550-2550.	1.4	8
30	Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study. Blood, 2021, 138, 3617-3617.	1.4	1
31	Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results. Blood, 2021, 138, 1476-1476.	1.4	1
32	First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib. Blood, 2021, 138, 1474-1474.	1.4	5
33	Peripheral Blasts Are Associated with Response to Ruxolitinib and Outcome in Patients with Chronic-Phase Myelofibrosis. Blood, 2021, 138, 3624-3624.	1.4	0
34	Pro-Inflammatory and Pro-Oxidative Changes during Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). Blood, 2021, 138, 1479-1479.	1.4	1
35	Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. International Journal of Cardiology, 2020, 301, 163-166.	1.7	21
36	Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. Leukemia, 2020, 34, 488-498.	7.2	35

#	Article	IF	CITATIONS
37	Preliminary results of a counselling programme for fertility preservation in female cancer patients: The experience of the GEMME DORMIENTI network. European Journal of Cancer Care, 2020, 29, e13174.	1.5	3
38	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer, 2020, 126, 1243-1252.	4.1	106
39	ALK-negative anaplastic large cell lymphoma with "Hodgkin-like―cytomorphology and nuclear expression of PAX5. Pathology Research and Practice, 2020, 216, 152724.	2.3	2
40	Treatment-Free Remission in Chronic Myeloid Leukemia: Lights and Shadows. Hematology Reports, 2020, 12, 8950.	0.8	7
41	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. Journal of Clinical Medicine, 2020, 9, 3692.	2.4	2
42	Impact of SARS CoV-2 in hemoglobinopathies: a protective mechanism being from Beta chain Hemoglobin defects?. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020052.	1.3	12
43	Favorable outcome of chronic myeloid leukemia coâ€expressing e13a2 and e14a2 transcripts, treated with nilotinib. Hematological Oncology, 2020, 38, 607-610.	1.7	1
44	Pregnancy outcomes in patients treated with bosutinib. International Journal of Hematologic Oncology, 2020, 9, IJH26.	1.6	17
45	Current clinical strategies and emergent treatment landscapes in leukemic transformation of Philadelphia-negative myeloproliferative neoplasms. Expert Review of Hematology, 2020, 13, 1349-1359.	2.2	2
46	CML-206: ReSETting SETD2/H3K36Me3 Deficiency as a New Therapeutic Strategy in Blast Crisis Chronic Myeloid Leukemia Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S236-S237.	0.4	0
47	Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. Therapeutic Advances in Hematology, 2020, 11, 204062072096612.	2.5	29
48	NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020083.	1.3	6
49	SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020031.	1.3	30
50	Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. Annals of Hematology, 2020, 99, 1525-1530.	1.8	9
51	Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. Blood Cancer Journal, 2020, 10, 66.	6.2	6
52	Lowâ€dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous <scp>TKls</scp> . American Journal of Hematology, 2020, 95, E260-E263.	4.1	15
53	Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. Leukemia, 2020, 34, 2260-2261.	7.2	57
54	Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. Blood, 2020, 136, 2237-2240.	1.4	13

#	Article	IF	CITATIONS
55	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Realâ€world data. Hematological Oncology, 2020, 38, 372-380.	1.7	15
56	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood, 2020, 135, 534-541.	1.4	61
57	Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic. Blood, 2020, 136, 43-44.	1.4	11
58	Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE) Tj ETQq0 0	0 rgB 1.4 Ove	rlock 10 Tf 50
59	Multidimensional Vascular Evaluation in Patients Treated with Tyrosine Kinase Inhibitors (TKIs): From Plaque Formation to Evolution and Follow up on 150 Patients. Blood, 2020, 136, 54-54.	1.4	1
60	Prognostic Significance of Transcript-Type BCRâ€ABL1 in Chronic Myeloid Leukemia. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020062.	1.3	11
61	Sustained Transfusion Independence in Chronic Bone Marrow BM Failure under Long-Term Self-Administration of Moringa Oleifera. Saudi Journal of Medicine, 2020, 05, 50-52.	0.1	Ο
62	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. Blood, 2020, 136, 47-48.	1.4	0
63	lgM-Secreting Diffuse Large B-Cell Lymphoma (DLBCL) Is a Poor Prognostic Subset within the Non-Germinal-Centre-Type (GC-type): An Italian Multicentre Study. Blood, 2020, 136, 30-31.	1.4	Ο
64	Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. Blood, 2020, 136, 45-46.	1.4	1
65	Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib. Blood, 2020, 136, 8-9.	1.4	Ο
66	Impact on Mental Health, Disease Management and Socioeconomic Modifications in Hematological Patients during COVID-19 Pandemia in Italy. Blood, 2020, 136, 35-37.	1.4	4
67	New Perspectives and Challenges Regarding Fertility, Conception and Pregnancy in Hemoglobinopathies. a Multidisciplinary Report of 66 Outcomes. Blood, 2020, 136, 22-23.	1.4	Ο
68	Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica, 2019, 104, 93-101.	3.5	62
69	Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. Annals of Hematology, 2019, 98, 2329-2338.	1.8	17
70	TREATMENT PATTERNS IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKAEMIA IN ROUTINE CLINICAL PRACTICE: THE SIMPLICITY ITALIAN POPULATION. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019025.	1.3	7
71	The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network †Rete Ematologica del Lazio per i Linfomi' (RELLI). Leukemia and Lymphoma, 2019, 60, 3386-3394.	1.3	11
72	Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy. Annals of Hematology, 2019, 98, 2609-2611.	1.8	13

#	Article	IF	CITATIONS
73	"Variantâ€specific discrepancy when quantitating BCRâ€ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.―Is dPCR the key?. European Journal of Haematology, 2019, 103, 272-273.	2.2	24
74	Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 3330-3332.	1.3	5
75	Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. Annals of Hematology, 2019, 98, 1885-1890.	1.8	10
76	Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. International Journal of Cardiology, 2019, 288, 124-127.	1.7	19
77	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. Hematological Oncology, 2019, 37, 418-423.	1.7	3
78	Double remission of simultaneously occurring secondary AML and CLL by venetoclax monotherapy. Acta Oncológica, 2019, 58, 888-890.	1.8	2
79	Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the realâ€life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Hematological Oncology, 2019, 37, 296-302.	1.7	53
80	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica, 2019, 104, 1589-1596.	3.5	58
81	Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Cancer Medicine, 2019, 8, 2041-2055.	2.8	63
82	Flow Cytometry Assessment of CD26 + Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia. Cytometry Part B - Clinical Cytometry, 2019, 96, 294-299.	1.5	28
83	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. Blood Advances, 2019, 3, 4280-4290.	5.2	66
84	Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. Journal of Hematology and Oncology, 2019, 12, 131.	17.0	45
85	Back to the future: Treatmentâ€free remission and pregnancy in chronic myeloid leukemia. European Journal of Haematology, 2019, 102, 197-199.	2.2	15
86	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. Annals of Hematology, 2019, 98, 889-896.	1.8	10
87	Prospective Monitoring of Peripheral Blood CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation. Blood, 2019, 134, 2919-2919.	1.4	2
88	Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database. Blood, 2019, 134, 498-498.	1.4	11
89	Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party. Blood, 2019, 134, 2931-2931.	1.4	2
90	Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial. Blood, 2019, 134, 1652-1652.	1.4	3

#	Article	IF	CITATIONS
91	Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience. Blood, 2019, 134, 839-839.	1.4	2
92	Mantle CELL Lymphoma (MCL) in Elderly Patients (PTs): The Experience in Real-Life of Rete Ematologica Laziale Linfomi (RELLI). Blood, 2019, 134, 5257-5257.	1.4	0
93	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. Blood, 2019, 134, 4153-4153.	1.4	0
94	Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study. Blood, 2019, 134, 2936-2936.	1.4	0
95	Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way. Blood, 2019, 134, 4142-4142.	1.4	0
96	Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian â€~Back to Life' project. Quality of Life Research, 2018, 27, 1545-1554.	3.1	9
97	Sexual health in patients with hematological malignancies: a neglected issue. Supportive Care in Cancer, 2018, 26, 1699-1701.	2.2	9
98	Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. Annals of Hematology, 2018, 97, 1577-1580.	1.8	32
99	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. Hematological Oncology, 2018, 36, 561-569.	1.7	46
100	Cardiovascular toxicity in patients with chronic myeloid leukemia treated with secondâ€generation tyrosine kinase inhibitors in the realâ€life practice: Identification of risk factors and the role of prophylaxis. American Journal of Hematology, 2018, 93, E159-E161.	4.1	26
101	Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study. Annals of Hematology, 2018, 97, 1357-1367.	1.8	14
102	Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial. Blood, 2018, 132, 393-404.	1.4	392
103	Efficacy and safety of ruxolitinib in intermediateâ€1 IPSS risk myelofibrosis patients: Results from an independent study. Hematological Oncology, 2018, 36, 285-290.	1.7	29
104	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. Annals of Hematology, 2018, 97, 95-100.	1.8	32
105	The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia. Frontiers in Oncology, 2018, 8, 555.	2.8	18
106	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. Leukemia Research, 2018, 74, 86-88.	0.8	23
107	Successful Decitabine Treatment in Unfit, Elderly Patients with Acute Myeloid Leukemia following Chronic Myeloproliferative Neoplasm. Acta Haematologica, 2018, 140, 231-233.	1.4	5
108	Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib. Expert Opinion on Drug Safety, 2018, 17, 623-628.	2.4	10

#	Article	IF	CITATIONS
109	Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. Frontiers in Oncology, 2018, 8, 194.	2.8	84
110	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. British Journal of Haematology, 2018, 183, 35-46.	2.5	7
111	Chronic myeloproliferative disorders: is quality-of-life the new goal?. Current Medical Research and Opinion, 2018, 34, 1345-1347.	1.9	2
112	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter studyâŽ. Seminars in Hematology, 2018, 55, 248-255.	3.4	24
113	Chronic Myeloid Leukemia Diagnosed during Pregnancy: Therapy, Outcomes and Follow-up. Blood, 2018, 132, 4255-4255.	1.4	6
114	Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy. Blood, 2018, 132, 4254-4254.	1.4	6
115	Gimema Registry of Conception/Pregnancy in Adult Italian Patients Diagnosed with Chronic Myeloid Leukemia (CML): Report on 166 Outcomes. Blood, 2018, 132, 43-43.	1.4	10
116	International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. a GIMEMA and HOVON Study. Blood, 2018, 132, 1750-1750.	1.4	6
117	Kinetics of BCR-ABL after TKI Interruption during Pregnancy in CML: A Multinational Retrospective Analysis. Blood, 2018, 132, 4263-4263.	1.4	6
118	Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Level. Comparison of Qpcr, d-PCR and CD26 Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR). Blood, 2018, 132, 4244-4244.	1.4	2
119	Evaluation of the prognostic role of tumourâ€associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDGâ€PET assessment. Hematological Oncology, 2017, 35, 69-78.	1.7	25
120	The BCRâ€ABL1 transcript type influences response and outcome in <scp>P</scp> hiladelphia chromosomeâ€positive chronic myeloid leukemia patients treated frontline with imatinib. American Journal of Hematology, 2017, 92, 797-805.	4.1	71
121	Decitabine treatment of multiple extramedullary acute myeloid leukemia involvements after essential thrombocytemia transformation. Acta Oncológica, 2017, 56, 1331-1333.	1.8	7
122	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. Haematologica, 2017, 102, 1530-1536.	3.5	15
123	HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia. Leukemia Research, 2017, 61, 1-5.	0.8	12
124	The DESTINY of chronic myeloid leukeamia. Lancet Haematology,the, 2017, 4, e303-e304.	4.6	3
125	Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice. Annals of Hematology, 2017, 96, 1591-1593.	1.8	3
126	Firstâ€line treatment selection and early monitoring patterns in chronic phaseâ€chronic myeloid leukemia in routine clinical practice: SIMPLICITY. American Journal of Hematology, 2017, 92, 1214-1223.	4.1	36

#	Article	IF	CITATIONS
127	Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN. Annals of Hematology, 2017, 96, 387-391.	1.8	14
128	Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature. Therapeutics and Clinical Risk Management, 2017, Volume 13, 751-755.	2.0	4
129	Hodgkin's lymphoma in a man with dilated cardiomyopathy and paraneoplastic ataxia: a therapeutical challenge. Hematology Reports, 2017, 9, 6944.	0.8	1
130	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget, 2017, 8, 79073-79086.	1.8	63
131	Rotation of nilotinib and imatinib for firstâ€line treatment of chronic phase chronic myeloid leukemia. American Journal of Hematology, 2016, 91, 617-622.	4.1	10
132	Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients. Journal of Hematology and Oncology, 2016, 9, 63.	17.0	18
133	Primitive "Spindle Cell Variant―(Sarcomatoid Variant) Diffuse Large B-Cell Lymphoma of the Uterine Cervix: Description and Outcome of a Rare Case. International Journal of Gynecological Pathology, 2016, 35, 593-597.	1.4	10
134	Frontline Dasatinib Treatment in a "Real-Life―Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. Neoplasia, 2016, 18, 536-540.	5.3	24
135	Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase. Haematologica, 2016, 101, e267-e268.	3.5	7
136	Management of pregnant chronic myeloidÂleukemia patients. Expert Review of Hematology, 2016, 9, 781-791.	2.2	55
137	Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. Leukemia, 2016, 30, 1615-1619.	7.2	16
138	Dasatinib first-line: Multicentric Italian experience outside clinical trials. Leukemia Research, 2016, 40, 24-29.	0.8	6
139	Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. Blood, 2016, 128, 3070-3070.	1.4	10
140	Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. Oncotarget, 2016, 7, 72311-72321.	1.8	26
141	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget, 2016, 7, 80083-80090.	1.8	24
142	The Neutrophil/Lymphocyte Ratio (N/L) Is a Prognostic Marker in Patients with Diffuse Large B Cell Lymphoma: A Prospective Study from the Lazio Lymphoma Registry. Blood, 2016, 128, 3050-3050.	1.4	0
143	Age and d <scp>PCR</scp> can predict relapse in <scp>CML</scp> patients who discontinued imatinib: The <scp>ISAV</scp> study. American Journal of Hematology, 2015, 90, 910-914.	4.1	181
144	The impact of dasatinib on pregnancy outcomes. American Journal of Hematology, 2015, 90, 1111-1115.	4.1	98

#	Article	IF	CITATIONS
145	Successful management of pregnancy and hepatic toxicity in a CML female patient treated with nilotinib : a case report and a review. Mediterranean Journal of Hematology and Infectious Diseases, 2015, 7, e2015020.	1.3	12
146	Differences among young adults, adults and elderly chronic myeloid leukemia patients. Annals of Oncology, 2015, 26, 185-192.	1.2	72
147	Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. Blood Cancer Journal, 2015, 5, e347-e347.	6.2	29
148	Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia, 2015, 29, 1823-1831.	7.2	77
149	Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. Experimental Hematology, 2015, 43, 1015-1018.e1.	0.4	51
150	Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leukemia Research, 2015, 39, 1055-1059.	0.8	57
151	Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months. Blood, 2015, 126, 2775-2775.	1.4	3
152	Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial. Blood, 2015, 126, 4025-4025.	1.4	7
153	Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study. Blood, 2015, 126, 5142-5142.	1.4	0
154	TYROSINE KINASE INHIBITORS AND PREGNANCY. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014028.	1.3	91
155	Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML). BioDrugs, 2014, 28, 17-26.	4.6	24
156	Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. American Journal of Hematology, 2014, 89, 119-124.	4.1	14
157	Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. Leukemia Research, 2014, 38, 1173-1176.	0.8	30
158	Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial. Journal of Clinical Oncology, 2014, 32, 1188-1194.	1.6	349
159	Gimema Registry of Conception/Pregnancy in Adult Patients Diagnosed with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs). Blood, 2014, 124, 1806-1806.	1.4	5
160	Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. Blood, 2014, 124, 3135-3135.	1.4	43
161	Subcutaneous Immunoglobulin (SCIG) in Responders to Intravenous Therapy with Chronic Immune Thrombocytopenia (ITP). Blood, 2014, 124, 5012-5012.	1.4	2
162	The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis. Blood, 2014, 124, 813-813.	1.4	4

#	Article	IF	CITATIONS
163	Effectiveness and Safety of Low Dose Eltrombopag Twice Weekly in ITP Patients That Achieved CR after 50mg Daily Standard Dose. Blood, 2014, 124, 2788-2788.	1.4	0
164	Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study. Drugs and Aging, 2013, 30, 629-637.	2.7	36
165	Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. Annals of Hematology, 2013, 92, 179-183.	1.8	12
166	A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias. New England Journal of Medicine, 2013, 369, 1783-1796.	27.0	944
167	Primary pulmonary Hodgkin Lymphoma simulating a mediastinal tumour: an uncommon occurrence Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013013.	1.3	3
168	Dysgeusia in patients with hematological malignancies: a reminder for hematologist. Journal of Oral Pathology and Medicine, 2013, 42, 352-353.	2.7	0
169	Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood, 2013, 121, 5138-5144.	1.4	49
170	Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. Haematologica, 2013, 98, 399-403.	3.5	42
171	Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs). Blood, 2013, 122, 1496-1496.	1.4	4
172	Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial. Blood, 2013, 122, 1498-1498.	1.4	8
173	Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party. Blood, 2013, 122, 258-258.	1.4	2
174	Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial. Blood, 2013, 122, 2738-2738.	1.4	2
175	Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML). Blood, 2013, 122, 4007-4007.	1.4	6
176	Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial. Blood, 2013, 122, 650-650	1.4	8
177	The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate. Blood, 2013, 122, 1486-1486.	1.4	0
178	Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment. Mechanisms of Ageing and Development, 2012, 133, 479-488.	4.6	9
179	Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood, 2012, 120, 761-767.	1.4	110
180	Evaluation of residual CD34 ⁺ Ph ⁺ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during firstâ€line nilotinib therapy. Cancer, 2012, 118, 5265-5269.	4.1	13

#	Article	IF	CITATIONS
181	Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial. Blood, 2012, 120, 3747-3747.	1.4	6
182	Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica, 2011, 96, 1457-1461.	3.5	58
183	Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. Leukemia Research, 2011, 35, 1164-1169.	0.8	28
184	Tattoo related pyoderma/ectyma gangrenous as presenting feature of relapsed acute myeloid leukaemia: An exceptionally rare observation. Injury, 2011, 42, 546-547.	1.7	17
185	Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. Experimental Hematology, 2011, 39, 653-665.e6.	0.4	37
186	Severe Peripheral Arterial Disease During Nilotinib Therapy. Journal of the National Cancer Institute, 2011, 103, 1347-1348.	6.3	145
187	Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with secondâ€generation tyrosine kinase inhibitors. American Journal of Hematology, 2011, 86, 523-525.	4.1	7
188	Reversible hair depigmentation in a patient treated with imatinib. Leukemia Research, 2011, 35, e64-e66.	0.8	19
189	Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. Journal of the National Cancer Institute, 2011, 103, 553-561.	6.3	362
190	Immunophenotype and intermediateâ€high international prognostic index score are prognostic factors for therapy in diffuse large Bâ€cell lymphoma patients. Cancer, 2010, 116, 5667-5675.	4.1	14
191	Pyrrolo[1,2â€b][1,2,5]benzothiadiazepines (PBTDs) exert their antiâ€proliferative activity by interfering with Akt–mTOR signaling and bax:bclâ€2 ratio modulation in cells from chronic myeloid leukemic patients. Cancer Science, 2010, 101, 991-1000.	3.9	6
192	Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With Imatinib Mesylate: GIMEMA CML Working Party Analysis. Journal of Clinical Oncology, 2010, 28, 2748-2754.	1.6	56
193	Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy Blood, 2010, 116, 3413-3413.	1.4	2
194	Abstract 2143: High-Resolution Molecular Karyotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Identifies Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes. , 2010, , .		1
195	Retrospective Application of European LeukemiaNet Provisional Criteria for Second-Generation TKI Chronic Myeloid Leukemia. Blood, 2010, 116, 2270-2270.	1.4	0
196	Bcr-Abl Kinase Domain Mutations in Imatinib and in Second-Generation Tyrosine Kinase Inhibitor Eras: Seven Years of Mutation Analysis, a Report by the GIMEMA CML Working Party. Blood, 2010, 116, 2279-2279.	1.4	0
197	Hammersmith Score Is Able to Identify Chronic Myeloid Leukemia Patients with Poor Prognosis Before Treatment with Second-Generation TKIs Blood, 2010, 116, 3409-3409.	1.4	2
198	Incidence and Mortality of Second Malignancies In 559 Patients with Chronic Myeloid Leukemia (CML) Treated with Imatinib Frontline: Data From the GIMEMA CML Working Party. Blood, 2010, 116, 2281-2281.	1.4	0

#	Article	IF	CITATIONS
199	BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis Blood, 2010, 116, 1230-1230.	1.4	2
200	One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806 Blood, 2010, 116, 3412-3412.	1.4	0
201	Imatinib In Very Elderly CML Patients: What Can We Achieve? Blood, 2010, 116, 1229-1229.	1.4	0
202	Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity Blood, 2010, 116, 3375-3375.	1.4	2
203	Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial. Journal of Clinical Oncology, 2009, 27, 3472-3479.	1.6	181
204	Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response. Clinical Cancer Research, 2009, 15, 1059-1063.	7.0	28
205	Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood, 2009, 113, 4497-4504.	1.4	173
206	Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood, 2009, 114, 2168-2171.	1.4	160
207	Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood, 2009, 114, 4939-4943.	1.4	62
208	High-Resolution Molecular Allelokaryotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Shows a High-Frequency of Uniparental Disomy and Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes Blood, 2009. 114. 2176-2176.	1.4	1
209	Peptide-Vaccine Treatment Associated with TKI Therapy in Patients with CML Is Able to Induce Immunologic, Cytogenetic and Molecular Responses: a Single Center Experience with Long-Term Follow up Blood, 2009, 114, 2185-2185.	1.4	1
210	Chronic Myeloid Leukemia (CML) Patients with "Suboptimal―Response to Imatinib (IM) According to European LeukemiaNet Criteria Have a Poorer Outcome with Respect to "Optimal―Responders: A GIMEMA CML WORKING PARTY Analysis Blood, 2009, 114, 2196-2196.	1.4	3
211	Prospective Exploratory Phase II Studies of A Rotating Regime of Nilotinib and Imatinib for Frontline Treatment of Philadelphia POSITIVE (Ph+) Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL) Blood, 2009, 114, 4972-4972.	1.4	1
212	Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients Blood, 2009, 114, 2199-2199.	1.4	0
213	Pegylated Liposomal Doxorubicin, Bleomycin, Vinblastine and Dacarbazine (CBVD) in the Treatment of Advanced Primary Cutaneous Lymphomas Blood, 2009, 114, 3717-3717.	1.4	1
214	Real-Life Analysis of Dasatinib in Chronic Phase CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib Blood, 2009, 114, 2211-2211.	1.4	0
215	Late Development of Cytogenetic Abnormalities in Ph Negative Cells of Chronic Myeloid Leukemia Patients Treated with Imatinib Blood, 2009, 114, 1108-1108.	1.4	0
216	Ph-Negative Hematopoiesis Emerging After Successful Treatment of Chronic Myeloid Leukemia Displays Severe and Persistent Telomeric Loss Which Is Particularly Prominent in Patients with Acquired Cytogenetic Abnormalities Blood, 2009, 114, 2164-2164.	1.4	0

#	Article	IF	CITATIONS
217	Long-Term Outcome of Complete Cytogenetic Responders After Imatinib 400 mg in Late Chronic Phase, Philadelphia-Positive Chronic Myeloid Leukemia: The GIMEMA Working Party on CML. Journal of Clinical Oncology, 2008, 26, 106-111.	1.6	48
218	153Sm: its use in multiple myeloma and report of a clinical experience. Expert Opinion on Investigational Drugs, 2008, 17, 1379-1387.	4.1	15
219	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood, 2008, 111, 1834-1839.	1.4	284
220	Characterization of Ph-negative abnormal clones emerging during imatinib therapy. Cancer, 2007, 109, 2466-2472.	4.1	29
221	PYRROLO[1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs) induce apoptosis in K562 cells. BMC Cancer, 2007, 7, 207.	2.6	6
222	Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs):  A New Class of Agents with High Apoptotic Activity in Chronic Myelogenous Leukemia K562 Cells and in Cells from Patients at Onset and Who Were Imatinib-Resistant. Journal of Medicinal Chemistry, 2006, 49, 5840-5844.	6.4	56
223	Catamenial Bernard-Horner's Syndrome Related to Thoracic Endometriosis. Annals of Thoracic Surgery, 2006, 82, e24-e25.	1.3	4
224	Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825. Blood, 2006, 107, 4571-4572.	1.4	7
225	Comparison Between Patients With Philadelphia-Positive Chronic Phase Chronic Myeloid Leukemia Who Obtained a Complete Cytogenetic Response Within 1 Year of Imatinib Therapy and Those Who Achieved Such a Response After 12 Months of Treatment. Journal of Clinical Oncology, 2006, 24, 454-459.	1.6	42
226	Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. Clinical Cancer Research, 2006, 12, 7374-7379.	7.0	475
227	Long Term Follow up on Patients with Ph-Abnormal Clones Emerged during Imatinib Therapy Blood, 2006, 108, 2116-2116.	1.4	0
228	Pyrrolo[1,2-B][1,2,5] benzodiazepines (PBTDs) Compounds Induce Apoptosis in Chronic Myeloid Leukaemia Cells from Patients at Onset, Imatinib and Second Generation TK Inhibitors (Dasatinib,) Tj ETQq0 0 0 r	gBIT4/Over	lo c k 10 Tf 50
229	ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2005, 23, 4100-4109.	1.6	350
230	New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia. Leukemia Research, 2001, 25, 349-351.	0.8	13
231	Monosomy X as a recurring sole cytogenetic abnormality associated with myelodysplastic diseases. Cancer Genetics and Cytogenetics, 1997, 93, 140-146.	1.0	21
232	Study of clonality in myelodysplastic syndromes: Detection of trisomy 8 in bone marrow cell smears by fluorescence in situ hybridization. Leukemia Research, 1996, 20, 551-557.	0.8	16
233	High-dose chemotherapy in adult acute myeloid leukemia: Rationale and results. Leukemia Research, 1996, 20, 535-549.	0.8	14